MHRA Tackles Post Brexit Distribution Worries
Executive Summary
Companies importing medicines from the EU into the UK in the event of a no-deal Brexit could face a lot of complications. The UK medicines regulator, the MHRA, has come up with one idea for easing the import requirements in such a scenario.
You may also be interested in...
EC, UK And Ireland Step Up No-Deal Brexit Contingency Plans
The European Commission and the UK and Irish governments are all stepping up their preparations for a no-deal Brexit.
UK's No-Deal Brexit Plans Revealed For Pharma Sector
The UK government has published “technical notices” explaining what would change in the drug regulatory arena in the event of a no-deal Brexit, and what stakeholders need to do to prepare. Companies will be expected to stockpile medicines in the immediate run-up to the UK's departure from the EU.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.